Trial Profile
A prospective study of apatinib in the treatment of patients with recurrent or metastatic ovarian cancer
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 12 Jun 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 12 Jun 2018 New trial record